Funding for this research was provided by:
JPSP KAKENHI (JP17H04144)
Grant-in-Aid for Challenging (19K22781)
Text and Data Mining valid from 2020-02-17
Received: 10 December 2019
Accepted: 6 February 2020
First Online: 17 February 2020
Ethics approval and consent to participate
: This study was approved by the institutional review board of Meiji Pharmaceutical University (No. 3007). The provision and analysis of DPC and JANIS data was approved by the Kyushu University Institutional Review Board for Clinical Research (29–364). Informed consent was not required from the patients, because the study was a retrospective analysis using anonymized data.
: Not applicable
: HF reports fees from Astellas Pharma, Inc., Nippon Becton–Dickinson Co., Ltd, Novartis Pharma K.K., Pfizer, Inc., MA reports fees from Janssen Pharmaceutical K.K., Takeda Pharmaceuticals, Inc., and Pfizer, Inc.